Migrane attack medicine
Suviray 70mg/ml ( Erenumab ) Injection in pre-filled syringe
|Dose||Injection in pre-filled syringe|
|Product Type||Finished Product|
|Form Of Medicine||Injection in prefilled syringe|
|Packaging Type||1 vial|
SUVIRAY :Erenumab - (Aimovig) is a new medication used for preventing migraine attacks. It received the Food and Drug Administration's (FDA) approval on May 17, 2018. It belongs to a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonist. CGRP-R is a chemical produced by the body that acts on blood vessels in the brain which are believed to be responsible for the development of migraines. Erenumab reduces the number of monthly migraine attacks by blocking CGRP-R receptors on blood vessels.